It is now known that KRAS mt NSCLC is a heterogeneous disease, which differs from other oncogene-derived tumors, and that this heterogeneity may be related to concurrent genomic alterations such STK11 or TP53, different subtypes of KRAS or tumor dependence/independence on KRAS. Here, STK11 is linked to non-small cell lung carcinoma.